Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( PIONEER REAL Canada)
Authors' conclusion
In PIONEER REAL Canada, participants treated with oral semaglutide in routine clinical practice experienced clinically relevant reductions in HbA1c and BW and increased treatment satisfaction.
Study context
- Population
- Adults with T2D, treatment-naive to injectable glucose-lowering medication, routine clinical practice in Canada; mean age 58.6 years, HbA1c 8.0%, body weight (BW) 93.7 kg
- Participants
- 182 adults
- Outcome
- Change in HbA1c from baseline
- Follow-up
- End of study (EoS)
Methodological detailsmulticentre, open-label, non-interventional, 34- to 44-week
- Multicentre
- Open-label
- Non-interventional
- 34- to 44-week
Main finding
As reported in the abstract
EoS
| Group | Value | p |
|---|---|---|
| Oral semaglutide | estimated change −1.09 (95% CI −1.24–-0.94) % points | p < .0001 |
Oral semaglutide
Valueestimated change −1.09 (95% CI −1.24–-0.94) % points
pp < .0001
Observational data: associations, not effects.
Secondary outcomes
Change in BW from baseline · end of the study (EoS)
- Estimated change in BW from baseline to EoS
- −7.17% (95% CI −8.24, −6.11; p < .0001)
HbA1c <7% · EoS
- Participants with HbA1c <7%
- 53.7%
Composite: HbA1c reduction ≥1% point plus BW reduction ≥3% / ≥5% · EoS
- HbA1c reduction ≥1% point plus BW reduction ≥3%
- 39.3%
- HbA1c reduction ≥1% point plus BW reduction ≥5%
- 31.6%
Treatment satisfaction (Diabetes Treatment Satisfaction Questionnaires (DTSQ)) · EoS
Points
- Treatment satisfaction significantly increased: DTSQ status (p < .0001)
- +4.47
- DTSQ change (p < .0001)
- 11.83
Remaining on oral semaglutide · EoS
- Remained on oral semaglutide
- 75.3%
- Received oral semaglutide 14 mg
- 55.5%
Safety
- No new safety signals were identified for oral semaglutide
Original publication
Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( PIONEER REAL Canada). Diabetes Obes Metab. Published 11 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →